Long-Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study.

Area of Science:

• Neurology
• Neurosurgery
• Movement Disorders

Background:

• Subthalamic deep brain stimulation (STN-DBS) is used to manage Parkinson's disease (PD).
• STN-DBS is known to reduce antiparkinsonian medication needs post-surgery.
• Longitudinal and comparative data on this medication reduction effect are limited.

Purpose of the Study:

• To compare medication use trajectories in STN-DBS treated PD patients versus non-surgically treated controls.
• To analyze long-term effects of STN-DBS on antiparkinsonian medication requirements.

Main Methods:

• Retrospective analysis of antiparkinsonian medication data.
• Study included PD patients who underwent STN-DBS (1999-2010) and matched controls.
• Controls were selected based on age at onset, baseline characteristics, sex distribution, and comorbidities.

Main Results:

• Levodopa-equivalent daily doses (LEDD) in 74 STN-DBS patients decreased by 33.9-56.0% from baseline over 14 years.
• LEDDs in 61 control patients increased over approximately 10 years, showing significant group divergence.
• Dopamine agonists showed the most substantial difference in medication class between groups.

Conclusions:

• Chronic STN-DBS is associated with sustained lower LEDD in PD patients compared to controls over 14 years.
• STN-DBS facilitates long-term reduction in antiparkinsonian medication needs.